In summary (Figure 7), we demonstrated that NCX1 is highly expressed in prostate cancer and that the reverse-mode NCX1 activity inhibitor KB-R7943 can inhibit cell cycle progression, migration, and proliferation both in vivo and in vitro. Here, SLC8A1 is linked to Familial prostate cancer.